Page 1 Page 2 Page 3 Page 4 Page 5 Page 6 Page 7 Page 8 Page 9 Page 10 Page 11 Page 12 Page 13 Page 14 Page 15 Page 16 Page 17 Page 18 Page 19 Page 20 Page 21 Page 22 Page 23 Page 24 Page 25 Page 26 Page 27 Page 28 Page 29 Page 30 Page 31 Page 32 Page 33 Page 34 Page 35 Page 36 Page 37 Page 38 Page 39 Page 40 Page 41 Page 42 Page 43 Page 44ng Trends Data Analysis Biosimilars ernative Medicine Individualized Care Data Analysis Data Analysis 25 MONDAY, SEPTEMBER 18, 2017 Data Analysis MONDAY, SEPTEMBER 18, 2017 Data Analysis l Data Analysis l Data AnalysisSymposium 8 Data AnalysisSymposium 8 Data Analysis l 10:00 am – 12:00 pm Kinase Inhibitors in Pediatric Patients: Experiences, Pharmacology & Future Applications DISCOVERY TRACK Offers both CME and CPE Credit UAN #0238-0000-17-013-L01-P ACPE – 2 CONTACT HOURS/APPLICATION-BASED CO-CHAIRS: Jonathan Constance, PhD, Assistant Professor, Univ of Utah G. W. ‘t Jong, MD, PhD, Academic Pediatrician & Clinical Pharmacologist, Assistant Professor of Pediatrics, Internal Medicine & Pharmacology, Univ of Manitoba TARGET AUDIENCE: This Symposium will be useful for pharmacologists, pharmacists, clinicians or graduate/postgraduate trainees wishing to better understand the implications of kinase inhibitor (KI) use among pediatric patient populations, with an emphasis on pediatric malignancies. GOALS AND OBJECTIVES: Following completion of this activity, the learner will be able to: 1. Describe the current and prospective scope of kinase inhibitor therapy among children with cancer, while highlighting unique challenges in a developmental context; 2. Identify advances in the utilization of precision medicine (eg, genetic characteristics) to tailor KI therapeutic regimens in pediatric cancer patients. Moreover, participants will be able to relate how lessons learned in the last decade from KI use in the adult population will influence pediatric KI use. A special emphasis on being able to describe the benefits and risks associated with combination therapy (KI and conventional chemotherapy or other molecularly-targeted agent) in pediatric cancer; 3. Recognize that the confluence between normal growth and developmental processes in children and the introduction of KI therapy may reveal pediatric-specific adverse events, such as the disruption of normal bone growth. 10:00 – 10:10 am Introduction Jonathan Constance, PhD, Assistant Professor, Univ of Utah 10:10 – 10:30 am The History, Current Practice & Prospects of Tyrosine Kinase Inhibitor Therapy in Pediatric Acute Lymphoblastic Leukemia Patients: The Expanding Role for Kinase Inhibitor Therapy Elizabeth Raetz, MD, Professor of Pediatrics, Univ of Utah 10:30 – 10:50 am Pharmacokinetics of Kinase Inhibitors in Children: Factors Influencing Variability Sharyn Baker, PharmD, PhD, Chair & Professor, Div of Pharmaceutics & Pharmaceutical Chemistry, Ohio State Univ 10:50 – 11:10 am Pharmacodynamics of KIs in Children: Markers of Effect & Mechanisms of Resistance R. Donald Harvey, PharmD, Associate Professor & Director, Phase I Section, Winship Cancer Inst of Emory Univ 11:10 – 11:30 am Going Forward: KI Therapy for Pediatric Diseases G. W. ‘t Jong, MD, PhD, Academic Pediatrician & Clinical Pharmacologist, Assistant Professor of Pediatrics, Internal Medicine & Pharmacology, Univ of Manitoba 11:30 am – 12:00 pm Panel Discussion and Q&A Symposia